1-2 of 2
Chris Del Nagro
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Subcutaneous, every-four-week maintenance dosing of a novel protein S antibody is well-tolerated and substantially reduces bleeding rates: Results from A phase 1/2 multidose study of VGA039 in patients with von Willebrand disease

Free
Allison Wheeler, Shrinath Kshirsagar, Adam Giermasz, Johnny Mahlangu, Gabriela Yamaguti-Hayakawa, Savita Rangarajan, Genevieve Moyer, Christine Kempton, Almudena Tercero, Paul Sims, Sandip Panicker, Chris Foo, Eileen Sawyer, Chris Del Nagro, Gary Patou, Benjamin Kim, Nicoletta Machin
Journal: Blood
Blood (2025) 146 (Supplement 1): 308.
https://doi.org/10.1182/blood-2025-308
Published: 2025
Journal Articles

VGA039 as a protein S-targeted hemostatic promoting monoclonal antibody, promotes in-vitro thrombin generation in plasma samples from subjects across a broad range of bleeding disorders, including von Willebrand disease, hemophilia A, hemophilia B and hemophilia C

Free
Alina He, Paul Sims, Joanne Chan, Christopher Horvath, Benjamin Kim, Gary Patou, Chris Del Nagro, Sandip Panicker, Shruti Kharat, Savita Rangarajan, Shrimati Shetty
Journal: Blood
Blood (2025) 146 (Supplement 1): 1277.
https://doi.org/10.1182/blood-2025-1277
Published: 2025